Abstract: The present invention relates to process for preparing a drug delivery composition comprising the steps of a) preparing a masterbatch comprising a drug and a first polymer by (i) extruding the first polymer, wherein said first polymer has a melting temperature below 140° C.; and (ii) introducing the drug during extrusion of the first polymer, with a drug content between 0.1% and 90%, based on the total weight of the masterbatch; and b) introducing the masterbatch in a polymer-based matrix during production of the drug delivery composition, wherein step a) is performed at a temperature at which the first polymer is in a partially or totally molten state, and step b) is performed at a temperature at which both the first polymer and at least a polymer of the polymer-based matrix are in a partially or totally molten state.

Abstract: The present invention relates to a medical device (10), preferably a micro robot for application inside a body, preferably for application inside a human body (2). The medical device (10) includes a body part (11) and a tail part (12). A controlling line (13) is attached to the tail part (12). The controlling line (13) has a tensile strength sufficient to pull back the device from a target location and/or control its velocity and column strength not sufficient to push the medical device (10).

Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.

Abstract: The present invention relates to a compound represented by the following formula (I): A[B—(C)v]w??(I), wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of such compounds in cosmetic and therapeutic applications. The invention also relates to the use of such compounds for reducing photodegradation and/or photoinstability of pharmaceuticals and cosmetics. The invention further relates to a material comprising a support and such a compound adhered to said support.

Abstract: The treatment or prevention of a Coronaviridae infection, and conditions related thereto; in particular a Coronaviridae infection in humans. In particular, the compounds, pharmaceutical compositions and medicaments for treating and/or preventing a Coronaviridae infection and/or its long-term consequences. The uses and methods for assessing a Coronaviridae infection or the efficacy of a treatment of such infections.

Abstract: The present invention relates to a compound represented by the following formula (I): A[B—(C)v]w, wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of such compounds in cosmetic and therapeutic applications. The invention also relates to the use of such compounds for reducing photodegradation and/or photoinstability of pharmaceuticals and cosmetics. The invention further relates to a material comprising a support and such a compound adhered to said support.

Abstract: The invention relates to an endoprosthesis (1), in particular a vascular stent or a heart stent, comprising at least one body (3) part. At least one area (5,6) of an outer surface, preferably the whole outer surface, of the at least one body part (3) is provided with thrombogenic fibers (2). The invention further relates to methods of manufacturing endoprostheses (1).

Abstract: The invention relates to a medical implant (1) that is adapted to repair or close defect (D), in particular an opening in a ventricular, atrial, or septal wall (W). The medical implant (1) may, in particular, be a patch. It comprises an adhesive composition (6). It further comprises two states, wherein in the first state, the medical implant (1) can be deployed to an implant site while the adhesive composition (6) is inactive. It can be brought into a second state by an activation mechanism. The adhesive composition (6), in the second state, is curable by a curing mechanism.

Abstract: The invention relates to medical implant (1) that is adapted to close a defect (D) or a cavity, preferably a defect in an atrial or septal wall (W) or a left atrial appendage. The implant (1) comprises an occlusion device (6) and has two states. It is adapted to, in a first state, be deployed to a defect site (D), where it can be brought into a second state by an activation mechanism. It is adapted to close said defect (D) in said second state.

Abstract: The invention is directed to a method of determining properties in a vessel or the heart (V) of a patient. It comprises the steps of placing an element in a vessel or the heart(V) and determining a propulsion force (2) acting on the element. Furthermore, at least one of acceleration (3) and velocity (4) of the element is determined. At least one property of a neighbouring medium of the element is determined based on the propulsion force and at least one of acceleration (3) and velocity (4) of the element.

Abstract: The invention relates to a positioning device (1) comprising a distal part (8) that is adapted to be delivered through a defect, preferably an opening in a ventricular or atrial septum. It comprises a mechanism to selectively expand the distal part (8), such that before expansion, it can be deployed through said defect, and upon expansion, is mechanically prevented from being retracted through the same defect. Thus, the positioning device (1) is temporarily engaged at the defect site.

Abstract: The present invention relates to a set of particles comprising at least one bioadhesive particle of formula (I): {A-[(B)n-C]m}.X??(I), in which A represents a polymer core, B represents a linear linker, C represents a functional group, n is 0 or 1, and m is an integer from 1 to 1025, and where said bioadhesive particle encapsulates or is attached to at least one active agent X. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of the set of particles in medicine, in particular for treating and/or preventing skin, mucosa, or eye cornea diseases or conditions.

Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.

Abstract: Biomarkers and uses thereof in monitoring, assessing, and/or treatment of viral infections, or inflammatory diseases, disorders, or conditions, or cancer.

Abstract: The present invention relates to compositions and methods for treating cancers in a subject in need thereof. The invention more particularly relates to methods of treating cancers by inhibiting PLA2-GIB in a subject in need thereof.

Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.

Abstract: A compound of formula (Ib?) or anyone of its metabolites or a pharmaceutically acceptable salt thereof for use for treating and/or preventing cancer and/or dysplasia wherein R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1 R2, —SO3H, —O— SO2—OR3, —O—P(?O)(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl, said alkyl being optionally mono- or di-substituted by a hydroxyl group, a -A-(CH2)m—B—NRaRb group, or a —(O—CH2—CH2)p—O—Ra group. The present disclosure also relates to a compound of formula (IVb?) or a pharmaceutically acceptable salt thereof for use for treating and/or preventing cancer and/or dysplasia.

Abstract: The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer.

Abstract: A medical device (10), preferably a micro robot for application inside a body, and more preferably for application inside a human body (2). The medical device (10) includes a body part (11) and a tail part (12). A recapture line (13) is attached to the tail part (12). The recapture line (13) has a tensile strength which is sufficient to pull back the device while the column strength of the recapture line (13) not sufficient to push the medical device (10).

Abstract: A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(?O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl; each R? is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(?O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, or other groups and further relates to A compound of formula (IV): or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein V, Z, R, R?, n, and n? are as described above.